-
Sector Analysis
Spinal Muscular Atrophy Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Spinal Muscular Atrophy (SMA) market through 2033. The diagnosed prevalent cases of SMA across the seven major markets are expected to increase from 18,621 cases in 2023 to 19,202 cases by 2033. The SMA market across the 7MM was valued at $2.7 billion in the 2023 baseline year. Over the 10-year forecast period, the market is projected to grow at...
-
Thematic Analysis
Blockbuster Drugs on Patent Cliffs: Strategic Intelligence
A patent cliff occurs when a drug loses its patent protection, allowing biosimilars and generics to enter the market. This typically leads to a sharp drop in revenue for the originator company as market share declines. Pharmaceutical companies need to think about their business strategies to remain competitive and sustain profitability as patents expire. As a result, pharmaceutical companies will face increased pressure to innovate, diversify, and show a strong differentiated pipeline. The next patent cliff, between 2025 and 2030,...
-
Sector Analysis
Clinical Trials:Â Biomarkers to Support Clinical Endpoints
This report provides a comprehensive analysis of biomarkers in clinical trials. The purpose of this report is to offer valuable insights into the landscape of clinical trials involving biomarkers by highlighting trends and patterns across various dimensions. Ultimately, this report serves as a resource for researchers, clinicians, and industry stakeholders seeking to understand the evolving role of biomarkers in clinical trials. The insights derived from this analysis can inform future research directions, enhance trial design, and contribute to feasibility planning. This...
-
Sector Analysis
Critical Assessment of Trump Administration’s Renewed Efforts to Introduce IRP in the US via the MFN Executive Order
In May 2025, US President Donald Trump issued an executive order (EO) stating that pharmaceutical companies should provide Most Favored Nation (MFN) prices to American consumers or face steep penalties. The EO calls for the introduction of International Reference Pricing (IRP) in the US. Based on extensive knowledge of IRP and detailed IRP 360 profiles for 75 markets, in this report GlobalData examines the implications of IRP use by the US for pharmaceutical companies, for payers, and for patient access...
-
Sector Analysis
Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034. GlobalData estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and...
-
Sector Analysis
Pulmonary Arterial Hypertension in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market. Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
-
Product Insights
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Global Clinical Trials Review, 2025" provides an overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Clinical trials scenario. This report provides top line data relating to the clinical trials on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Renal Failure Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Renal Failure - Global Clinical Trials Review, 2025" provides an overview of Renal Failure Clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025" provides an overview of Respiratory Syncytial Virus (RSV) Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Respiratory Syncytial Virus (RSV) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Sicca Syndrome (Sjogren) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025" provides an overview of Sicca Syndrome (Sjogren) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.